5HT3R

5-HT3 receptor (5-HT3R) is a ligand-gated ion channel that binds serotonin (5-HT) and mediates fast excitatory neurotransmission. It is the sole ionotropic receptor within the broader family of serotonin receptors, in contrast to the G protein–coupled 5-HT receptors. Upon activation by 5-HT, the receptor channel opens to permit cations such as Na+, K+, and Ca2+ to flow, producing rapid depolarization.

Structure and subunits: The receptor is pentameric. In humans, five subunits have been identified: HTR3A, HTR3B, HTR3C, HTR3D, and HTR3E. The 5-HT3A subunit can form functional homomeric channels, while coassembly with 5-HT3B and other subunits alters pharmacology, conductance, and kinetics. Expression of subunits varies by tissue, with HTR3A and HTR3B being the most widely studied in brain and enteric nervous system; C, D, and E are less well characterized and often have restricted distribution.

Distribution and function: 5-HT3 receptors are found in the central nervous system, including regions such as the area postrema and nucleus tractus solitarius, as well as on peripheral neurons in the enteric nervous system and vagal afferents. Activation of these receptors contributes to nausea and vomiting, modulation of pain signaling, anxiety-related processes, and regulation of gut motility.

Pharmacology and clinical relevance: Antagonists of the 5-HT3 receptor, such as ondansetron, granisetron, dolasetron, and tropisetron, are widely used to prevent chemotherapy-induced nausea and vomiting. In irritable bowel syndrome with diarrhea (IBS-D), selective antagonists like alosetron reduce symptoms but may cause constipation and rare ischemic colitis. There are fewer clinically used 5-HT3 receptor agonists; current research explores receptor modulation for pain and mood-related conditions.

History: The 5-HT3 receptor was identified and cloned in the 1990s as the first ionotropic serotonin receptor, marking a distinction from the other, G protein–coupled 5-HT receptors.